Moss, 29 March 2017
Gentian Diagnostics AS (OSE: GENT-ME) is pleased to announce that it
has achieved design verification on its product G-CAL (Gentian
Calprotectin Immunoassay), a novel test for diagnosing inflammation
in blood samples with automated analyzers.
G-CAL will now enter the validation phase, the very last step in
Gentian's development process. Commercial launch of G-CAL is
expected in 3Q/17.
For further information, please contact:
Bård Sundrehagen
CEO, Gentian Diagnostics AS
E-mail: Bard.sundrehagen@gentian.no
Cell Phone: +47 924 14 117
ABOUT GENTIAN DIAGNOSTICS AS
Gentian Diagnostics AS is a medical diagnostics company listed on
Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".
Gentian is headquartered in Moss, Norway, with a representative
office in China and distribution subsidiaries in Sweden and USA.
Gentian designs, develops and markets in vitro diagnostic reagents
(IVD) based on its proprietary Nanosense technology. The goal is to
offer efficient and accurate reagents for major clinical chemistry
platforms with a focus within the areas of kidney disease, cardiac
disease, inflammation and veterinary medicine. The Nanosense
technology will enable users to move assays from low volume
immunology platforms to fully automated, high throughput instruments
with shorter turnaround times, better workflow and improved cost
efficiency.